Attovia Therapeutics, Inc. — Form 4/A
Filed August 28, 2026 · analyzed by the Insider Agent
4/A
▲ Likely positive
significance 78/100
What the filing says
Director WALSH COLIN (ATTO) bought 3.1M shares (~$12.5M) on the open market (97% of holdings). Open-market insider purchase — historically a bullish signal.
Why this rating
Open-market insider purchase — historically a bullish signal.
Tradability signal
NO TRADE
No trade: positive news with only +0.1% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.13% over 4 hrs, n=14).
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $20.70 ▼ 0.14% | at our read · backfill $20.73 | +10 min · backfill $20.73 ▲ 0.00% |
The stock had already moved +0.14% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.